Calcium-activated potassium channel subunit beta-1 (BK channel subunit beta-1) (BKbeta) (BKbeta1) (Hbeta1) (Calcium-activated potassium channel, subfamily M subunit beta-1) (Calcium-activated potassium channel subunit beta) (Charybdotoxin receptor subunit beta-1) (K(VCA)beta-1) (Maxi K channel subunit beta-1) (Slo-beta-1) (Slo-beta)
1_MVKKL 6_ VMAQK 11_ RGETR 16_ ALCLG 21_ VTMVV 26_ CAVIT 31_ YYILV 36_ TTVLP 41_ LYQKS 46_ VWTQE 51_ SKCHL 56_ IETNI 61_ RDQEE 66_ LKGKK 71_ VPQYP 76_ CLWVN 81_ VSAAG 86_ RWAVL 91_ YHTED 96_ TRDQN 101_ QQCSY 106_ IPGSV 111_ DNYQT 116_ ARADV 121_ EKVRA 126_ KFQEQ 131_ QVFYC 136_ FSAPR 141_ GNETS 146_ VLFQR 151_ LYGPQ 156_ ALLFS 161_ LFWPT 166_ FLLTG 171_ GLLII 176_ AMVKS 181_ NQYLS 186_ILAAQ
1: Regulatory subunit of the calcium activated potassium KCNMA1 (maxiK) channel. Modulates the calcium sensitivity and gating kinetics of KCNMA1, thereby contributing to KCNMA1 channel diversity. Increases the apparent Ca(2+)/voltage sensitivity of the KCNMA1 channel. It also modifies KCNMA1 channel kinetics and alters its pharmacological properties. It slows down the activation and the deactivation kinetics of the channel. Acts as a negative regulator of smooth muscle contraction by enhancing the calcium sensitivity to KCNMA1. Its presence is also a requirement for internal binding of the KCNMA1 channel opener dehydrosoyasaponin I (DHS-1) triterpene glycoside and for external binding of the agonist hormone 17-beta-estradiol (E2). Increases the binding activity of charybdotoxin (CTX) toxin to KCNMA1 peptide blocker by increasing the CTX association rate and decreasing the dissociation rate